Hosted on MSN1mon
FDA approves SPRAVATO as first monotherapy for MDD
TITUSVILLE, N.J. - Johnson & Johnson (NYSE:JNJ) has received approval from the U.S. Food and Drug Administration (FDA) for SPRAVATO® (esketamine) nasal spray as a standalone treatment for adults ...
pharmaphorum1d
FDA approves Janssen’s ketamine-based nasal antidepressant
The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...
MarketWatch1mon
Johnson & Johnson Gets FDA OK For Spravato as Monotherapy
Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy for adults with treatment-resistant depression. J&J on Tuesday said the green ...